Background
Spiritual well-being (Sp-WB) is a resource that supports adaptation and resilience, strengthening quality of life (QOL) in patients with cancer or other chronic illnesses. However, the relationship between Sp-WB and QOL in patients with chronic GVHD (cGVHD) remains unexamined.
Methods
52 participants completed the Functional Assessment of Chronic Illness Therapy – Spiritual Well-Being (FACIT-Sp) questionnaire as part of a multidisciplinary study of cGVHD.
Results
Sp-WB was generally high (Mean 37.06, SD 9.5). Those with the lowest Sp-WB had significantly longer time since diagnosis of cGVHD (p=0.05) than those with higher Sp-WB. There were no associations between Sp-WB and demographics, cGVHD severity, or intensity of immunosuppression. Participants with the lowest Sp-WB (N=11) reported inferior physical (p = .0009), emotional (p = .003), social (p = .027), and functional well-being (p = < 0.0001) as well as lower overall QOL (p = <0.0001) compared to those with higher Sp-WB. They also had inferior QOL (M 54.88, S.E. 4.19) relative to population norms (M=80.1, S.E. 0.55). Differences between those with the lowest and those with better Sp-WB consistently exceeded the minimal clinically significant difference for all subscales and for overall QOL. Controlling for physical, emotional and social well-being, Sp-WB was a significant independent predictor of contentment with QOL.
Conclusions
Our results suggest that Sp-WB is an important factor contributing to the QOL of patients with cGVHD. Research is needed to identify factors that diminish Sp-WB and to test interventions designed to strengthen this coping resource in patients experiencing the late-effects of treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.